Unmet needs in CML

FOR NEWLY DIAGNOSED PATIENTS

Are your CML patients getting the response you anticipated with their initial TKI?

Most newly diagnosed patients don’t reach MMR within the 1st year of treatment^1-3

Graphic showing that for newly diagnosed patients up to 73% (1G TKI) and up to 54% (2G TKI) did not achieve MMR by 12 months.

Some patients discontinued their 1st TKI due to adverse reactions^3-5:

Graphic showing that up to 14% of patients discontinued their 1st TKI due to adverse reactions in their first year.

Patients with CML need the efficacy of a TKI to manage their disease, but Ars can make navigating treatment challenging for some.

PATIENT PROFILES

What initial TKI considerations could help give your patients with Ph+ CML-CP a strong start?

To date, no single agent has been studied against all current standard-of-care TKI options for newly diagnosed patients.

2G, 2nd generation; AR, adverse reaction; CML, chronic myeloid leukemia; MMR major molecular response; Ph+ CML-CP, Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase; TKI, tyrosine kinase inhibitor.

Learn about Novartis Patient Support™ options>

References: 1. Hochhaus A, Saglio G, Hughes TP, et al. Leukemia. 2016;30(5):1044-1054. 2. Cortes JE, Saglio G, Kantarjian HM, et al. J Clin Oncol. 2016;34(20):2333-2340. 3. Brümmendorf TH, Cortes JE, Milojkovic D, et al. Leukemia. 2022;36(7):1825-1833. 4. Saglio G, Kim D-W, Issaragrisil S, et al. N Engl J Med. 2010;362(24)(suppl):1-15. 5. Kantarjian H, Shah NP, Hochhaus A, et al. N Engl J Med. 2010;362(24):2260-2270. 6. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for Chronic Myeloid Leukemia V.3.2025. ©National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed December 12, 2024. To view the most recent and complete version of the guidelines, go to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 7. Scemblix. Prescribing information. Novartis Pharmaceuticals Corp.

Unmet needs in CML

Are your CML patients getting the response you anticipated with their initial TKI?

What initial TKI considerations could help give your patients with Ph+ CML-CP a strong start?

Important Safety Information

Indication